Technical Reports on Biotech Equities -- Opko Health, Otonomy, Pacific Biosciences of California, and Portola Pharma

Monday, September 25, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 25, 2017 /PRNewswire/ --

If you want a Stock Review on OPK, OTIC, PACB, or PTLA then come over

to and sign up for your free customized report. Zacks reported that despite some challenges in 2016, it sees the trend reversing for the Biotech space in 2017 with more FDA approvals, new product sales ramp
up, R&D success and innovation, strong clinical study results, and continued strong performance of some legacy products. The research firm further noted that these positive factors are expected to continue to contribute to the sector's growth through the rest of this year and maybe the next. This morning, observes the following companies: Opko Health Inc. (NASDAQ: OPK), Otonomy Inc. (NASDAQ: OTIC), Pacific Biosciences of California Inc. (NASDAQ: PACB), and Portola Pharmaceuticals Inc. (NASDAQ: PTLA). Learn more about these stocks by downloading their comprehensive and free reports from member's area at:

Opko Health 

Miami, Florida headquartered Opko Health Inc.'s shares finished Friday's session 3.55% higher at $6.71. A total volume of 7.42 million shares was traded, which was above their three months average volume of 4.53 million shares. The stock has gained 9.46% in the last month. The Company's shares are trading above their 50-day moving average by 7.55%. Moreover, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have a Relative Strength Index (RSI) of 62.31.

On September 14th, 2017, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.

On September 19th, 2017, Opko Health announced that BioReference Laboratories, an Opko Health company and one of the largest commercial laboratories in the US, has formed a national affiliation with The Garage, a dynamic, healthcare technology change agent, to provide clinicians with advanced tools to guide quality, value-based care. Combining The Garage's Bridge - an advanced technology platform - with BioReference's deep knowledge of diagnostics and test results will provide physicians with unparalleled insight into their patients' health status. OPK complete research report is just a click away at:


Shares in San Diego, California headquartered Otonomy Inc. ended the day 4.35% lower at $3.30 with a total trading volume of 833,883 shares. The stock is trading 76.34% below its 50-day moving average. Shares of the Company, which focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the US, have an RSI of 18.74.

On August 30th, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'.

On September 13th, 2017, Otonomy announced a set of immediate actions to preserve capital, extend its cash runway, and build shareholder value following the recent negative AVERTS-1 Phase-3 trial results for OTIVIDEX in Ménière's disease. Following the suspension of OTIVIDEX development, the Company has implemented a workforce reduction totaling approximately one-third of personnel not involved in OTIPRIO® (ciprofloxacin otic suspension) commercial support. Additionally, no clinical trials will be initiated during the remainder of this year. The complimentary report on OTIC can be downloaded at:

Pacific Biosciences of California 

Menlo Park, California headquartered Pacific Biosciences of California Inc.'s stock dropped 2.85%, closing the session at $5.12. A total volume of 777,092 shares was traded. The Company's shares have surged 19.35% in the last one month, 38.01% in the previous three months, and 34.74% on an YTD basis. The stock is trading 18.90% above its 50-day moving average and 15.20% above its 200-day moving average. Additionally, shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 58.05. Sign up for your complimentary research report on PACB at:

Portola Pharmaceuticals 

On Friday, shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. finished the session 2.54% higher at $54.12. A total volume of 1.21 million shares was traded. The stock has surged 141.18% on an YTD basis. The Company's shares are trading above their 200-day moving average by 31.45%. Moreover, shares of Portola Pharma, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 41.11. Get free access to your research report on PTLA at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store